Interferon-g-inducible protein 10 is a potent chemoattractant for natural killer cells and activated T lymphocytes. It also displays angiostatic properties and some antitumor activity. Tumor necrosis factor-a (TNF-a) is a powerful immunomodulating cytokine with demonstrated tumoricidal activity in various tumor models and the ability to induce strong immune responses. This prompted us to evaluate the antitumor effects of recombinant parvoviruses designed to deliver IP-10 or TNF-a into a glioblastoma. When Gl261 murine glioma cells were infected in vitro with an IP-10-or TNF-a-transducing parvoviral vector and were subcutaneously implanted in mice, tumor growth was significantly delayed. Complete tumor regression was observed when the glioma cells were coinfected with both the vectors, demonstrating synergistic antitumor activity. In an established in vivo glioma model, however, repeated simultaneous peritumoral injection of the IP-10-and TNF-a-delivering parvoviruses failed to improve the therapeutic effect as compared with the use of a single cytokine-delivering vector. In this tumor model, cytokine-mediated immunostimulation, rather than inhibition of vascularization, is likely responsible for the therapeutic efficacy.
Introduction
Gliomas are highly malignant brain tumors. The median survival time of patients diagnosed with glioblastoma multiforme is less than 1 year. These tumors are particularly refractory to most conventional anticancer therapies, including surgical resection, radiation therapy and chemotherapy. 1, 2 The limited efficacy of current standard treatments makes it necessary to investigate alternative therapeutic approaches, among which those based on immunostimulation seem promising. 3, 4 One approach relies on cytokines inducing an increased immune response within the tumor. 5, 6 Another involves ex vivo manipulation of effector cells (dendritic cells, DCs); for example, stimulating them with specific antigens or promoting their maturation. 7 A hallmark of glioblastoma is the high degree of neovascularization observed within the tumor. [8] [9] [10] Inhibition of angiogenesis might be a powerful strategy for impeding the growth of vascularized tumors. The therapeutic effectiveness of targeting glioma-induced angiogenesis has indeed been demonstrated in various experimental systems. [10] [11] [12] [13] [14] [15] Interferon-g (IFN-g)-inducible protein 10 (IP-10/ CXCL10) is a member of the ELR À CXC chemokine family. It is a potent chemoattractant for natural killer and activated T cells, acting through the CXCR3 receptor. 16, 17 It also displays angiostatic properties. [18] [19] [20] It is synergistically induced in various cell types by IFN-g, other cytokines and Toll-like receptor ligands. 21 Antitumor effects of IP-10, used alone 22 or in synergy with other cytokines, 23 have been demonstrated in vivo by forced expression in tumors and also in adoptive T-cell therapy. 24, 25 As both the angiostatic and the immunomodulatory properties of this chemokine appear essential for its antitumor activity in vivo, 20, 26 we have sought to evaluate its protective effect against mouse glioma cells implanted into syngeneic immunocompetent and nude mice.
Tumor antigen presentation by DCs to T cells in lymphoid organs is crucial to the induction of antitumor immune responses. Tumor necrosis factor-a (TNF-a) is reported to induce DC maturation 27 and subsequently to increase the ability of DCs to stimulate T cells. [28] [29] [30] Viral vectors can be used to deliver therapeutic proteins into tumors. The most frequently used are adenoviruses, adeno-associated viruses, retroviruses, lentiviruses and herpes simplex viruses. 10, 15, 23, 31 Autonomous parvoviruses are small, nonintegrating single-stranded DNA viruses that replicate without the assistance of a helper virus. 32 Certain rodent parvoviruses, hereafter referred to as parvoviruses, replicate preferentially in tumor-derived and oncogene-transformed human and rodent cells and show oncosuppressive activity in laboratory animals. 33 Because of these properties, both natural [34] [35] [36] and recombinant parvoviral vectors 22, [37] [38] [39] [40] [41] [42] have attracted interest as potential tools for treating cancer. The recombinant parvoviruses developed so far are called capsid replacement vectors, because the capsid-encoding region is replaced with a therapeutic transgene whereas the genes coding for the nonstructural viral proteins NS1 and NS2 are retained, allowing amplification of the viral genome and transactivation of the second viral promoter in susceptible cells. 39 These vectors consequently fail to produce progeny viruses upon infection, 43 but produce high levels of transgene products. 39, 41, 42 Furthermore, the rodent parvoviruses, MVMp and H-1, are weakly immunogenic in, and rarely pathogenic to, adult animals, these features being potentially advantageous in cancer therapy. These properties and the promising antitumor effects observed in various tumor models with recombinant parvoviruses armed with interleukin-2 39, 40 or specific chemokines 22, 41, 42 make such vectors appear as attractive potential novel therapeutics. In this study, we have evaluated the antitumor effects of glioma-targeting parvovirus-mediated delivery of IP-10 and TNF-a, hypothesizing that expression of these proteins in gliomas might produce antitumor effects at three levels: (i) IP-10-mediated recruitment of activated T and natural killer cells to the site of the tumor (immunoattraction and stimulation), (ii) inhibition of tumor angiogenesis by IP-10 and (iii) TNF-a-mediated maturation of DCs in the presence of (recombinant) virus-infected tumor cells. Our results show that coexpressed IP-10 and TNF-a act synergistically against target glioma cells. We also show that in the tumor model studied, the immunostimulatory activity of IP-10 most likely contributes more to its antitumor effect than do its angiostatic properties.
Materials and methods

Cell cultures
The human glioma cell lines A-172, U-87 MG, U-373 MG and U-138 MG were obtained from the Tumor Bank of the German Cancer Research Center. Murine Gl261 and MT539 glioma cells were a gift from Drs Pierre-Yves Dietrich and Paul Walker (Division of Oncology, University Hospital, Geneva, Switzerland). A-172, U-87 MG, Gl261 and 293T cells were grown in Dulbecco's modified Eagle's medium, U-373 MG cells were maintained in minimum essential medium (Sigma-Aldrich, Taufkirchen, Germany), U-138 MG cells were cultured in RPMI (Sigma) and MT539 cells were maintained in low-glucose Dulbecco's modified Eagle's medium (Gibco, Eggenstein, Germany). All media were supplemented with 100 mg ml À1 penicillin, 100 U ml À1 streptomycin and 10% fetal calf serum. NB324K and A9 cells were grown in minimum essential medium supplemented with 5% fetal calf serum and antibiotics. Cell viability was determined by 0.4% (w/v) Trypan Blue (Sigma) exclusion.
Plasmids and viruses
The MVMp-based parvoviral vector pChi-MVMp/D800 and the H-1-based parvoviral vector pChi-hH1/D800 have been described earlier. 43 The human IP-10 cDNA was cloned in the vector plasmids pChi-MVMp/D800 and pChi-hH1/D800 by inserting a 393-bp BamHI-ClaI fragment containing the IP-10-encoding cDNA into the multiple cloning sites of the vectors, producing pChiMVMp/IP-10 and pChi-hH1/IP-10, respectively. The murine TNF-a cDNA was cloned by inserting a 707-bp NotI-BamHI fragment of plasmid pSV23SMTNF (obtained from the BCCM/LMBP Plasmid Collection, Gent, Belgium) generated by PCR amplification with the primers: 5 0 -GGGCGGCCGCGCGCGCGCATGAGCACAGA AAGCATGATC-3 0 and 5 0 -GGGGATCCGGATCCTCACAGAGCAATGAC TCCAAAGTAGACCTG-3 0 between the NotI and BamHI restriction sites of the parvoviral vectors, producing pChi-MVMp/TNF-a and pChi-hH1/TNF-a. To produce recombinant viruses, 2 Â 10 6 293T cells were cotransfected by the calcium phosphate procedure with 6 mg parvoviral vector DNA and 12 mg helper plasmid encoding the parvoviral structural proteins. 43 Virus stocks were extracted from cells 72 h post-transfection by medium removal, cell lysis in 50 mM Tris-HCl, 0.5 mM EDTA, and three rounds of freezing and thawing. Viruses were purified by iodixanol gradient centrifugation and titrated by means of an infected cell hybridization assay as described earlier. 43 Briefly, A9 (MVMp-derived vectors) or NB324K indicator cells (H-1-derived vectors) were incubated with 0.4 ml virus suspension for 1 h, further incubated for 48 h with complete medium and transferred to nitrocellulose filters (NC45; Schleicher & Schuell, Dassel, Germany). The filters were treated with 0.5 M NaOH-1.5 M NaCl to denature the DNA and were subsequently neutralized. The membranes were baked for 2 h at 80 1C, hybridized with a virus-specific replication units (RUs) per milliliter of virus suspension. As a rule, the titers of viral stocks ranged from 1 Â 10 6 to 2 Â 10 7 RU ml À1 . The MVMp wt and H-1 wt viruses were produced by infection of A9 or NB342K cells, respectively. They were titrated by plaque assay on A9 or NB342K indicator cells, respectively, as described earlier. 39 
Cytokine expression
For measuring in vitro IP-10 and TNF-a expression, cultures of 2 Â 10 5 glioma cells were infected with the corresponding gradient-purified recombinant virus suspension at a multiplicity of infection (MOI) of 3 RU per cell in a total volume of 0.4 ml. At this MOI, 94% of the cells are infected. After 1 h of incubation at 37 1C, the inoculum was supplemented with complete culture medium. The level of IP-10 or TNF-a released into the culture medium was measured every 24 h postinfection (p.i.). For the measurement of daily IP-10 or TNF-a secretion, the medium was collected, frozen at À80 1C and replaced with fresh medium. Specific enzyme-linked immunosorbent assays were used to measure IP-10 44 and TNF-a contents of culture supernatants (BD OptE1A Set mouse TNF; BD Biosciences Pharmingen, Heidelberg, Germany).
Tumor models and virus treatments
Cultures of murine glioma cells (3-5 Â 10 5 Gl261 cells) were infected in vitro with different recombinant or wildtype viruses and implanted subcutaneously (s.c.) into the right flanks of syngeneic female C57Bl/6 mice (CRWiga, Sulzfeld, Germany). Alternatively, for direct in vivo studies, 1 Â 10 6 Gl261 cells were implanted s.c. into the right flanks of C57/Bl6 mice and, after the tumors reached a diameter of 2-3 mm, each animal was treated with six peritumoral injections of a recombinant or wild-type virus (1 Â 10 6 RU per injection per animal). The mice (5-to 6-week-old females, five animals per cage) were maintained in isolators at 21-24 1C, 40-60% humidity. Tumor sizes were measured with a calliper two to three times a week, and the tumor volume was calculated for an ellipsoid according to the formula V ¼ p/6 Â length Â width Â height (mm Statistical analyses were performed with Sigma Stat (SPSS, Chicago, IL) and MedCalc (MedCalc Software, Mariakerke, Belgium) software packages. Statistically significant differences were determined by Student's unpaired t-test or by the nonparametric Mann-Whitney rank sum test. Differences were considered significant at Pp0.05.
Immunohistochemistry
For histological examinations, the tumors of animals treated in vivo as described above were resected, cryofixed or paraffin-embedded and immunostained as described earlier. 45 Briefly, the tumors were either paraffin-embedded or cryofixed in liquid nitrogen-cooled isopentane and stored at À80 1C before further processing. Then 6-mm sections were cut at À20 1C with a Microm Microtome, placed on Superfrost microscope slides (Fisher Scientific, Schwerte, Germany) and exposed to 4% paraformaldehyde. Nonspecific sites were blocked with 1% normal swine serum (Life Technologies, Eggenstein, Germany) in phosphatebuffered saline. For immunohistochemical investigations, the sections were incubated (1 h, 37 1C) with a monoclonal rat anti-mouse CD31 antibody (BD Pharmingen, Heidelberg, Germany) to identify endothelial cells. The sections were then exposed to biotinylated anti-rat Ig (1:100; 20 min, 37 1C; Amersham, Braunschweig, Germany) followed by incubation with alkaline phosphatase-streptavidin (1:150; 20 min, 37 1C; Amersham) and the staining reaction was visualized by adding Neufuchsin solution (DAKO, Glostrup, Denmark). The nuclei were counterstained with hematoxylin. As a negative control, the primary antibody was omitted or unrelated control immunoglobulins were used. Sections of each tumor having the largest cross-sectional diameter were measured and computer-assisted counting of the cross-sectioned CD31-positive vessels was performed on the total tumor section at 20-fold magnification. Then the average number of vessels per mm 2 (±s.e.m.) was determined for each group (n ¼ 8 per group). Computer-assisted morphometry was performed using tumor sections that were blinded to the operator.
A previously described custom-developed computerassisted image analysis device 45 was used to quantify necrotic area of the paraffin-embedded, hematoxylineosin-stained tumor sections having the largest crosssectional diameter. The ratio of the necrotic area to the total tumor area was calculated and expressed as a percentage.
MRI analysis
All magnetic resonance imaging (MRI) measurements were performed with a clinical 1.5 T MR scanner (Magnetom Vision, Siemens, Erlangen, Germany) using a home-built animal resonator. For morphological imaging, six transversal slices were acquired at a spatial resolution of 0.08 mm 3 using a T 2 -weighted spin-echo sequence (TR/TE ¼ 4000 ms per 96 ms). Physiological parameters were assessed by dynamic contrast-enhanced MRI. Using a T 1 -weighted spoiled gradient echo sequence (TR/TE/a ¼ 46 per 7 ms per 401), two transversal slices of (0.3 Â 0.3 Â 2.0) mm 3 resolution were acquired. When an imaging time of 7 s was reached, the measurement was repeated successively to cover a total measurement time of 10.5 min. After the third repetition, a gadolinium-based contrast agent (CA) (Omniscan; Amersham) was injected into the tail vein at dose D ¼ 0.1 mmol per kg body weight over an infusion time of t ¼ 5 s. Before imaging, each mouse was anesthetized by inhalation of 3% isofluorane in an NO/O 2 mixture (1:2) and an intravenous catheter was inserted into the tail vein for CA administration.
Dynamic contrast-enhanced MRI data were analyzed assuming a bidirectional CA exchange between the blood (plasma volume) and tissue (extravascular extracellular space) compartments. In the MR images for each pixel, TNF-a and the IFN-c-inducible protein 10 in mouse glioblastoma M Enderlin et al signal intensity was measured over time, yielding a signal time course. For each image pixel, CA enhancement in the tumor tissue was determined by calculating the amplitude (A) (relative signal enhancement with respect to the precontrast value) and the exchange rate constant (k ep ), which is a mixture of CA exchange velocity and tissue perfusion.
For comparison of treated with untreated animals, an averaged signal time course of the whole tumor was measured to calculate A and k ep . Finally, the mean values of A and k ep and standard deviations were determined for each group and intergroup comparisons were performed.
In vitro generation of mouse dendritic cells from bone marrow Dendritic cells were generated from mouse CD34 þ bone marrow cells isolated from the femurs and tibias of 7-to 12-week-old C57Bl/6 female mice as described earlier. 46 The erythrocytes were removed by incubation of the cell pellet with 0.84% ammonium chloride for 5 min at room temperature. After washing with complete RPMI medium, the cells were incubated with anti-CD34 þ antibodies (MEC14.7) 47 for 1 h at 4 1C. Subsequently, the cells were mixed with magnetic MiniMACS microbeads coated with anti-rat IgG (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions and incubated for 30 min at 4 1C. CD34 þ cells were then separated on MS columns (Miltenyi Biotec) according to the manufacturer's instructions. Purified cells were transferred to six-well plates (B3 Â 10 5 cells in 3 ml per well). DCs were grown in complete RPMI medium (5% fetal bovine serum, 40 ng ml À1 granulocyte macrophagecolony stimulating factor and 100 ng ml À1 FLT-3L) at 37 1C with 5% CO 2 and diluted every 2-3 days until used at day 9 of the culture.
In vitro DC maturation Two approaches were used: stimulation of DCs with tumor cell lysates and coculture of DCs with tumor cells. For the lysates, 2 Â 10 5 Gl261 cells were infected at an MOI of 3 RU per cell with Chi-MVMp/D800, ChiMVMp/TNF-a or wild-type virus. Three days p.i., the cells were collected, the supernatant discarded and the cell pellet frozen in 0.5 ml fresh medium. One freeze-thaw cycle was performed before the lysates were stored at À20 1C. DCs (2 Â 10 6 ) were stimulated for 48 h with the lysate obtained from 1 Â 10 5 tumor cells. Then the cultures were phenotyped and a pinocytosis assay was performed (see below). In the coculture approach, 1 Â 10 5 Gl261 cells were infected with wild-type MVMp, ChiMVMp/D800 or Chi-MVMp/TNF-a virus at an MOI of 3. Two days p.i., tumor cells were collected and cocultured with DCs at the ratio 1:100 (Gl261:DCs) for 48 h. Subsequent procedures were as for the lysates. DCs (3 Â 10 5 cells per sample) were labeled with different antibodies directed against cell surface markers (anti-CD80, CD86, DEC205 or MHCII). Anti-CD11c antibodies were used to differentiate DCs from Gl261 cells.
For measuring the pinocytotic activity, DCs were incubated with fluorescein isothiocyanate-coupled dextran (1 mg ml À1 , MW 40 000; Sigma). The cells (1.5 Â 10 5 per sample) were incubated at either 0 or 37 1C, washed twice with cold phosphate-buffered saline, fixed in phosphate-buffered saline þ 1% formalin and analyzed by fluorescence-activated cell sorting.
Results
Glioma cells are quite sensitive in vitro to infection by wild-type MVMp or parvovirus H-1 To evaluate the capacity of gliomas to be treated with parvoviruses, glioma cells of human origin (A-172, U-87 MG, U-138 MG and U-373 MG) and mouse origin (Gl261 and MT539) were tested in vitro for sensitivity to wild-type parvovirus infection. To this end, human glioma cells were infected with wild-type H-1 virus and mouse cells with MVMp, and their growth was monitored after virus infection as shown in Figure 1 . All cell lines tested proved to be sensitive to parvoviral infection, as shown by reduced cell growth or a decreased number of living cells after virus infection, as compared with buffertreated controls (Figure 1 ). Even at a very low MOI ( ¼ 2), wild-type parvoviruses displayed a great ability either to kill cells (U-373 MG, U-138 MG, Gl261) or to inhibit their growth (A-172, U-87 MG, MT539), in agreement with previous observations on human glioma cell lines. Figure 2a shows the results of a representative experiment. As compared with the control group, all groups receiving an implant of infected cells displayed a significant delay in tumor appearance (10-25 days) and, at the outset at least, slower tumor growth, these effects leading to a 75-100% smaller mean tumor volume on days 20-26. A small effect was observable even in animals implanted with Chi-MVMp/D800-infected Gl261 cells, but the effect was stronger when a transgene-transducing parvovirus, particularly ChiMVMp/TNF-a, was used. When the implanted cells had received both the IP-10-expressing and the TNF-aexpressing parvoviruses, inhibition of tumor growth was drastic (almost 100%) (Figure 2a) . Among the animals in this group, 50% (four out of eight) developed only very small tumors, which were no longer detectable by day 72 p.i. (Figure 2b) , and 100% of them survived until day 140 p.i., in contrast to the other groups of animals in which the survival was only slightly prolonged as compared with the groups implanted with mock-infected or Chi-MVMp/ D800-infected cells (Figure 2c) .
Of the 21 animals treated with Chi-MVMp/IP-10 plus Chi-MVMp/TNF-a in three independent experiments TNF-a and the IFN-c-inducible protein 10 in mouse glioblastoma M Enderlin et al (eight mice per group, two experiments and five mice per group, one experiment), only nine developed tumors. All of the tumors initially regressed, but growth of one of them (5%) resumed, making it necessary to kill the animal bearing it. By the end of the experiment, 17 mice (81%) were tumor-free and 3 (14%) had very small, nongrowing tumors. To evaluate whether a protective immunity was induced in tumor-free animals that experienced treatment with Chi-MVMp/IP-10 plus Chi-MVMp/TNF-a-infected tumor cells, 13 mice (eight and five mice from two independent experiments) were challenged with uninfected GL261 cells (10 6 and 5 Â 10 5 cells, respectively) implanted in their contralateral flank and monitored up to day 100 postchallenge. All the mice, except one, remained tumor-free, suggesting that a specific CTL (that is, memory T cells) response was induced.
To further investigate the involvement of T cells in the antitumor activity of Chi-MVMp/IP-10 and Chi-MVMp/ TNF-a, Gl216 cells coinfected in vitro with these vectors or mock-treated were implanted s.c. in immunocompetent C57Bl/6 mice and immunocompromised nude mice (Figure 3) . In this experiment, seven of the eight immunocompetent mice injected with Chi-MVMp/IP-10-and Chi-MVMp/TNF-a-infected cells developed tumors, but in four of them, the tumors regressed, so that five of eight animals were tumor-free at the end of the experiment (day 51) (Figure 3 ). Nude mice developed significantly larger tumors than immunocompetent mice, whether the implanted cells were infected or not. In nude mice, furthermore, there was no significant difference in mean tumor volume between the test and control groups. The tumors arising from Chi-MVMp/IP-10-and ChiMVMp/TNF-a-infected cells grew continuously in these mice, so that 100% of the animals had tumors by day 12 postimplantation and were killed on day 19 p.i. These very different responses recorded in nude and immunocompetent mice suggest that T cells are involved in the antitumor effects mediated by the cytokines expressed from the parvoviral vectors.
Peritumoral injections of Chi-MVMp expressing IP-10 and TNF-a inhibit Gl261 tumor growth Next, we examined antitumor effects on established tumors. For this, we performed repeated in vivo injections of the following viruses at sites of established subcutaneous gliomas: Chi-MVMp/IP-10, Chi-MVMp/TNF-a, both cytokine-transducing vectors combined, the vector devoid of transgene and wild-type MVMp. In this experiment, 1 Â 10 6 Gl261 glioma cells were implanted . MOI, multiplicity of infection; TNF-a, tumor necrosis factor-a.
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M Enderlin et al into the right flanks of syngeneic C57/Bl6 mice. When the tumors were palpable (2-3 mm 3 on day 5 postimplantation), six parvovirus injections were administered to each animal at the rhythm of one injection on days 5, 6, 7, 9, 11 and 13 postimplantation. The virus dose was 1 Â 10 6 RU per injection (100 ml). The group injected with both ChiMVMp/IP-10 and Chi-MVMp/TNF-a received either half a dose (0.5 Â 10 6 RU) or a full dose (1.0 Â 10 6 RU) of each vector per injection. Control (mock-treated) animals were injected with 100 ml phosphate-buffered saline. Figure 4 shows the observed tumor growth in the different groups of animals in one representative experiment. Only marginal effects were observed in animals injected with Chi-MVMp/D800 compared with the mocktreated group. In all groups treated with vectors expressing therapeutic transgenes (IP-10, TNF-a or both), tumor expansion was delayed by about 5 days. When it resumed, it was slower in these groups than in the mocktreated group (the mean tumor volume being 60-80% smaller on days 20 and 22 of the study). Although Gl261 cells were shown to be very sensitive to the killing effects of wild-type parvoviruses in vitro, in agreement with our previous observations with other tumor models 39 , wildtype virus and the control vector Chi-MVMp/D800 had little to no effect (never more than 25-35% inhibition) on progression of established Gl261 gliomas. It therefore appears that in vivo, the greater antitumor efficacy of the viral vectors, compared with the control viruses, can be ascribed to the effects of the transgenes delivered by the vectors. The relatively moderate effects of the viral vectors injected in established tumors can be assigned to the limited accessibility to tumor cells and to the low doses of viruses that were used in this setting. In contrast to the results obtained with in vitro-infected glioma cells (Figure 2 ), the antitumor effect was no stronger in animals receiving both cytokine-encoding vectors than in mice treated with only one.
As TNF-a is reported to induce, in synergy with IFN-g, production of IP-10 in various cells 21, [48] [49] [50] , we investigated whether this might be the case in Gl261 cells. We thus used a specific enzyme-linked immunosorbent assay to detect mouse IP-10 in the supernatants of Gl261 cell cultures 2 days after infection at MOI ¼ 3 RU per cell with Chi-MVMp/TNF-a, Chi-MVMp/IP-10 or ChiMVMp/D800. Whereas only marginal levels of mouse IP-10 (3-6 ng per 2 Â 10 5 Gl261 cells) were detected in the last two cases and in supernatants of mock-treated cells, significant levels (20-30 ng per 2 Â 10 5 cells) were detected in the supernatant of cells treated with Chi-MVMp/ TNFa. This represents up to 25% of the level produced after infection with Chi-MVMp/IP-10 (100-120 ng) under the same conditions. These results suggest a possible partial explanation for the synergistic antitumor effects of Chi-MVMp/TNF-a and Chi-MVMp/IP-10 in this system: as expression of TNF-a from its parvovirus vector appears to induce expression of endogenous IP-10, this expression might combine with IP-10 expression from Chi-MVMp/IP-10 to boost the IP-10 level above a critical threshold.
Parvovirus-transduced TNF-a supports necrosis development in the immunocompetent mouse/Gl261 glioblastoma model Solid tumor growth generally leads to the presence of numerous necrotic (dead and dying) cells at the center of the tumor. By examining sections of whole tumors from animals treated as in the experiment depicted in Figure 4 , it was possible to identify regional changes caused by treatment with the different viral vectors.
Histomorphometric examination of tumor sections revealed a proportionately higher necrotic area in the groups treated with TNF-a or both cytokine-transducing vectors ( Figure 5 ) than in the other groups. These data suggest that in the s.c. Gl261 glioblastoma model, TNF-a may be the main contributor to tumor necrosis development. Increased necrosis is in accordance with the delayed tumor growth observed in these groups. It is noteworthy that reduced tumor expansion, but less necrosis, was found in animals treated with the IP-10-expressing vector alone. The observed effect of TNF-a expression might be because of vascular damage and/or a direct effect of TNF-a on tumor cell death.
Blood vessel density analysis of gliomas treated with Chi-MVMp/IP-10 and Chi-MVMp/TNF-a The products of the transgenes delivered by the Chi-MVMp/TNF-a and Chi-MVMp/IP-10 recombinant viruses have immunostimulatory and possible antiangiogenic properties. As glioblastomas are particularly vascularized tumors, proteins capable of influencing blood vessel formation, directly or indirectly, are likely to have an important effect on glioblastoma formation and growth. It was thus interesting to estimate blood vessel density in tumor tissues collected after in vivo treatment of Figure 4 ). For this, the tissues were histomorphometrically examined after staining with anti-CD31 antibodies, used as markers of endothelial cells and microvascularization.
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c. Gl261 tumors (experiment depicted in
The experimental animals were divided into two sets. The first set comprised the three animals per group that were killed on day 10 of the study, 3 days after the third virus injection. Tumors from these animals were used to analyze the effects of the recombinant vectors on early tumor angiogenesis.
The second set comprised the eight animals per group that received six virus injections. Tumor growth was monitored until the animals were killed for ethical reasons, enabling us to evaluate the influence of the recombinant vectors on late tumor angiogenesis.
Ten days after tumor cell implantation, blood vessel density was lower in the groups treated with wild-type MVMp or with the control vector Chi-MVMp/D800 than in all the other groups. Compared with the buffer-treated group, the groups treated with transgene-transducing vectors showed no change in tumor angiogenesis at this stage of tumor development (data not shown).
In the second cohort, surprisingly, although tumor growth was clearly delayed in all groups treated with at least one transgene-expressing vector, no detectable change in total blood vessel density was observed by anti-CD31 staining (data not shown). As anti-CD31 staining does not distinguish functional from occluded vessels, we then compared our histological results with MRI measurements taking only functional vessels into account. In the MRI study, we compared Gl261-derived tumor vascularization in Chi-MVMp/IP-10-treated and buffer-treated animals. In this experiment, 1 Â 10 6 Gl261 cells were implanted s.c. in syngeneic mice, and treatments (five animals per group) were administered as described in the legend of Figure 3 . MRI was performed on days 15 and 22 after tumor cell implantation. No significant difference was observed between the two groups on either day (data not shown). These results suggest that in this model and within the limits of this set of time points, the antitumor effects observed with the parvovirus expressing IP-10 were likely because of the chemotactic activity of this chemokine rather than its antiangiogenic properties.
The TNFa-expressing vector promotes maturation of dendritic cells in vitro Recent advances in immunology have made it possible to develop effective immunotherapy using peripheral DCs against tumors of the central nervous system. 7 This prompted us to investigate the ability of our recombinant parvoviruses to induce maturation of DCs. For this, we cocultured DCs with parvovirus-infected tumor cells or cultured them with tumor lysates, monitoring changes in DC pinocytotic activity and surface-marker expression profile as signs of DC maturation.
In this experiment, DCs stimulated with Chi-MVMp/ TNF-a-infected tumor cells (at a 100:1 DC-to-tumor cell ratio) showed decreased pinocytotic activity, whereas DCs exposed to MVMp-or Chi-MVMp/D800-infected tumor cells did not (Figure 6a ). Coculture and incubation with lysate were equally effective, giving results comparable to those obtained with recombinant TNF-a (20 ng ml À1 ) used as a positive control (Figure 6a ). DCs exposed to Chi-MVMp/TNF-a-infected whole tumor cells or to the corresponding lysates also showed a slightly increased number of mature marker-positive cells (CD80-, CD86-and MHC II-positive cells), as illustrated in Figure 6b . Altogether, our results suggest that glioma cells infected with a TNF-a-expressing parvoviral vector induce, albeit moderately, DC maturation.
Discussion
IP-10 (CXCL10) has been shown in various tumor models to exert antitumor activity by recruiting activated T cells and natural killer cells and also by inhibiting tumor neovascularization. 10, 22, 25, [51] [52] [53] [54] [55] The antitumor activity of IP-10 alone is usually moderate, but can in some cases be markedly increased by combined therapy, in particular with interleukin-2 and interleukin-12.
23, 56 The properties of IP-10 led us to view it as a promising candidate for glioma therapy, especially when delivered locally, alone or in combination with TNF-a, by parvoviral vectors. Our in vitro data demonstrate that IP-10 and TNF-a are secreted in high amounts into the culture medium of mouse glioma cells infected with recombinant MVMp viruses expressing the corresponding genes. We further show that glioma cells infected with an IP-10-or TNF-atransducing vector significantly delayed tumor growth when implanted s.c. in mice, in contrast with buffertreated cells or with cells infected with the empty vector. When the cells to be implanted are coinfected with both TNF-a and the IFN-c-inducible protein 10 in mouse glioblastoma M Enderlin et al vectors, complete tumor regression is observed. IP-10 and TNF-a thus exert a synergistic antitumor effect in this system. We did not observe any synergy between IP-10 and TNF-a when the corresponding genes were delivered into established tumors by parvovirus vectors, although a therapeutic effect was observed with each vector alone. This suggests that synergy between TNF-a and IP-10 might be important only at an early stage of tumor development, before the tumors become palpable. TNF-a and IFN-g are known to act synergistically to induce IP-10 in various cell types. 21, 48, 49, 57 TNF-a alone is reported to induce IP-10 only marginally in keratinocytes, 49 astrocytes, 58 and neural precursor cells, 50 but to a significant level in fibroblasts. 21 Thus, TNF-a administered alone might induce sufficient IP-10 expression in the connective tissue to promote synergy with this chemokine. The IP-10 genes of various mammals show high similarity. This notably applies to the sequences of certain regulatory elements, such as the IFN-stimulated response element and two nuclear factor-kB-binding sites in the proximal promoter region of the gene. 59, 60 It might explain why human IP-10 is quite effective in the mouse glioma model used here. We show here that the TNF-aexpressing parvovirus, as opposed to the control vectors, induces expression of mouse IP-10 in Gl261 cells. Marginal constitutive expression of IFN-a was detected TNF-a and the IFN-c-inducible protein 10 in mouse glioblastoma M Enderlin et al by reverse transcription-PCR in all cases (including buffer-treated Gl261 cells), with a slight increase in cells infected with any of the tested parvoviruses. Whether this level of expression is sufficient to induce IP-10 expression through cooperation of IFN-a and TNF-a, and/or whether this induction is mediated by nuclear factor-kB signaling, is not known. Alternatively, these cytokines might synergize to induce production of other chemokines, which might in turn cooperate with IP-10 to chemoattract leukocytes 57 and further stimulate the antitumor response.
In contrast with others, 10,51,54,61 we did not detect any significant decrease in tumor vascular density (as measured by immunohistochemistry with anti-CD31 antibodies) in mice treated with Chi-MVMp/IP-10, Chi-MVMp/TNF-a or both. Although other studies indicate that IP-10 can inhibit tumor growth thanks to its antiangiogenic potential, 55 our data are in agreement with those of Ehtesham et al 5 , who did not observe any inhibition of angiogenesis in Gl26 mouse glioma cells treated with an adenovirus expressing IFN-g, TNF-a or both. TNF-a is a pleiotropic agent, displaying powerful immunomodulatory activity and able to induce necrosis and apotosis in neoplastic cells. 62 It also targets tumor neovascularization and induces endothelial cell death. [63] [64] [65] [66] Here we have observed increased necrosis in tumors treated with a TNF-a-expressing parvovirus. Whether this reflects TNF-a-induced vascular damage, a direct effect on Gl261 tumor cells, or both remains unclear.
TNF-a is also reported to induce DC maturation. 27, 30, 67 Interestingly, we have found glioma cells infected with Chi-MVMp/TNF-a to promote DC maturation in vitro. This opens prospects for promising developments, as gliomas are known to induce an immunosuppressive environment, notably by suppressing DC maturation. 68 Taken together, our results indicate that TNF-a and IP-10 delivered by parvoviral vectors are proficient antitumor agents, inhibiting tumor growth. When applied in combination, they can even induce complete regression of Gl261 glioma, and hence survival of treated animals. These effects are likely to be mediated by stimulation of cellular immune responses against Gl261 glioma, triggered probably by both cytokines and increased necrosis when the glioma is treated with Chi-MVMp/TNF-a. These findings suggest that cytokine/ chemokine delivery by parvoviral vectors could be an effective therapeutic strategy for malignant gliomas.
